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Conceptually,  one antibody could be directed against a  combining site structure  of 
another antibody; thus, the two antibodies would combine with each other and might be 
considered  at least partially complementary.  Since  the  combining regions  of antigen 
receptors on B lymphocytes are apparently identical with the combining regions of the 
antibodies that the cells produce  (1-8),  then complementary antibodies might also be 
considered complementary anti-receptor antibodies (9). By convention, one antibody is 
described as "idiotype," and the specific anti-antibody for it as anti-idiotypic. But these 
distinctions  may be arbitrary when  considering  the functional  relationships  between 
complementary antibodies or receptors. Thus, for convenience in this paper, we will refer 
to idiotype and anti-idiotype as complementary idiotypes or antibodies. 
Our  evidence  for complementary responses  is  derived  from a  model  developed by 
Cosenza  and  KShler  (4,  5).  In  their  studies,  A/He  mice  were  immunized  with  the 
phosphorylcholine  (PC) ~ binding IgA myeloma protein produced by the plasmacytoma 
TEPC-15  (T15),  induced in and carried by serial transplantation  in BALB/c mice. The 
antibody raised to T15 neutralized the specific antibody activity of mouse IgM to PC, and 
it specifically suppressed the response to immunization with PC antigens when it was 
given passively to adult BALB/c mice or was added to cultures of BALB/c spleen cells. 
Thus, the antibody raised against an antibody, i.e. T15, had activity against a normally 
induced antibody, and apparently it functioned as an anti-receptor antibody (5). 
Interestingly,  sera from mice immunized repeatedly with a  PC  antigen con- 
mined not only antibody against PC but also antibody reactive with T15  (10). 
Presumably,  such complementary antibodies occurring in the same individual 
might be autoregulatory.  This possibility was explored in the  present experi- 
ments  by  preimmunizing  mice  with  T15  before  measuring  their  response  to 
immunization  with  PC,  or  alternatively,  by  preimmunizing  with  PC  before 
measuring the response to immunization with T15. We find that prior repeated 
immunization with T15 markedly suppressed the response to PC and vice versa; 
however,  with  other  immunization  schedules,  complementary  responses  oc- 
curred simultaneously or sequentially in individual mice. 
* Supported by U. S. Public Health Service grants AI-10242 and AI-9268, and by NCI-CB-43998. 
' Abbreviations  used in this paper: FCA, Freund's complete adjuvant; FIA, Freund's incomplete 
adjuvant; HBSS, Hanks' balanced salt solution; KLH, keyhole limpet hemocyanin; M315, MOPC- 
315; MBSA, methylated bovine  serum albumin;  PC,  phosphorylcholine;  PFC,  plaque-forming 
cells; T15, TEPC-15. 
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Materials and Methods 
Mice.  All mice, except as noted below,  were A/He females 8- to  12-wk old purchased from 
The Jackson  Laboratory,  Bar Harbor,  Maine.  The biological function of two pools of antisera 
raised in A/He mice was checked in cultures of BALB/c spleen cells (5) and in neonatal BALB/c 
mice (11).  The BALB/c mice were purchased from Cumberland View Farms, Clinton, Tenn. 
Antigens and Immunizations.  A formalin-killed vaccine of  Diplococcus pneumoniae, R36A (4), 
is referred to as vaccine. Mice were immunized with 0.2 ml of vaccine containing 109 organisms/ml 
which produces peak 4-day responses (5).  PC is the major antigenic determinant mice respond to 
when immunized with the vaccine; the antibody is predominantly, but not solely, IgM (4, 11, 12). 
The C-polysaccharide extracted from R36A vaccine induces a  response to PC in doses of 1-10 ~g 
but induces immunologic paralysis to PC when given in doses of 400 ~g (13). 
A  comparable IgM response is induced by PC coupled to various protein carriers (14);  in the 
present  experiments p-azophenylphosphorylcholine  conjugated  to  keyhole  limpet  hemocyanin 
(PC-KLH) was also used as a  PC-containing antigen (14).  Mice were injected intravenously with 
0.2 ml containing 0.7 mg PC-KLH/ml,  or were injected in each hind foot pad with 0.05 ml of a 
mixture ofl part PCoKLH, 0.7 mg/ml; 1 part methylated bovine serum albumin (MBSA), 1 mg/ml; 
1 part Bordetella pertussis vaccine  (strain 37790,  lot T-59  187  kindly supplied through Dr.  H. 
Campbell, Jr., Biological Development, Eli Lilly & Co., Indianapolis, Ind.); and 3 parts Freund's 
incomplete adjuvant  (FIA)  (Difco  Laboratories,  Detroit,  Mich.)  for the  first  immunization.  A 
mixture of 2 parts PC-KLH, 1 part MBSA, and 3 parts FIA was used for subsequent immunizations 
in hind foot pads. 
2,4-Dinitrophenyl  (DNP)-Ficoll  (DNP3~AECM83)  prepared  by  Dr.  John  Inman  was  kindly 
supplied by Dr. Donald E. Mosier, NIAID, National Institutes of Health, Bethesda, Md. Mice were 
immunized intravenously with 0.2 ml of a  solution containing 10 ~g DNP-Ficoll in saline. 
Two myeloma proteins were used as antigens; the protein produced by the T15 plasmacytoma is 
an  IgA  which  binds  PC  (but  not  DNP);  and  the  protein  produced  by  the  MOPC-315  (M315) 
plasmacytoma, is an IgA which binds DNP (but not PC). The tumors were carried in the ascitic 
form, and the proteins were recovered from ascitic fluid. The ascitic fluid was partially reduced 
and alkylated. T15 was absorbed on PC-Sepharose,  eluted with 10  -2 M PC, extensively dialyzed, 
and concentrated or  lyophilized.  M315  was  absorbed on trinitrophenyl-Sepharose,  eluted  with 
normal acetic acid, dialyzed, and concentrated. For immunization, the purified proteins, 1 mg/ml, 
were homogenized in a  mixture of 1 part protein,  1 part MBSA albumin, and 2 parts Freund's 
adjuvant. Freund's complete adjuvant (FCA) (Difco Laboratories) was used for the first immuniza- 
tion; FIA was used for subsequent immunizations. Each immunization was in two depots of 0.05 
ml, either in abdominal skin or in hind foot pads. 
Spleen and Lymph Node Cells.  Individual spleens were gently teased apart in 5.0 ml of Hanks' 
balanced salt solution (HBSS) using forceps and a wire screen. The cells were washed twice in 5.0 
ml of HBSS and resuspended in 10.0 ml HBSS.  The number of cells recovered per spleen was 
determined on an aliquot using a Coulter Counter (Coulter Electronics Inc., Hialeah, Fla.). 1-2 × 
108 nucleated cells were usually recovered per spleen; 25 or 50 ~l (i.e.,  1/200 or 1/400 of a  spleen) 
was plated on each slide for assaying numbers of plaque-forming cells (PFC). 
After two or more foot pad injections, the popliteal nodes measured 3-5 mm in diameter.  The 
two nodes were pooled and a  suspension of single cells was prepared in the same manner as for 
spleens, except that after the final wash the cells were resuspended in 2.0 ml HBSS. The number of 
cells recovered per node was determined on a portion of the sample using a  Coulter Counter; 5  × 
108-2  ×  107 cells were  usually recovered from two nodes.  The numbers of cells recovered from 
nodes were equivalent whether foot pads had been injected with adjuvants alone or with the ad- 
juvants containing the antigens used.  Either 25 or 50 ~1 (i.e., the equivalent of 1/20 or 1/40 of a 
single lymph node) was plated on each slide for assaying numbers of PFC. 
Antibody  Titers  and  PFC.  Titration  of serum  antibody  to  PC  and  enumeration  of  cells 
producing such antibody were done using sheep erythrocytes (SRBC) coated with the C-polysac- 
charide of R36A vaccine (PC-SRBC)  (4).  Titration of serum antibody to T15 determinants and 
measurement of cells producing such  antibody were  done  using SRBC  coated  with  T15  (T15- 
SRBC).  Chromium chloride was used for coating with both antigens; reproducible coating was 
achieved using chromium chloride in Tris buffer, pH 5.4, and carefully filtered and washed SRBC 
(13). 
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saline containing 59'0 heat-inactivated fetal calf serum. Wells contained 50 ~1 of diluted serum and 
50 ~1 of a 0.15% suspension of coated or noncoated erythrocytes. Trays were shaken, incubated at 
37°C  for 1 h,  and placed overnight in the refrigerator.  The titer of antibody was taken as the 
reciprocal,  logs,  of the  highest  serum  dilution  which  caused  agglutination as  indicated by  a 
dispersed  pattern of  sedimentation  of  erythrocytes.  2 
For assaying numbers of  PFC, 25 or 50 ~l of  cell  suspension was mixed with 50 /~l  of  a 5% 
suspension of  target  erythrocytes  in  0,3  ml  of  0.5%  agarose in  HBSS. The mixture  was  spread  on  a 
glass  slide.  Slides  were prepared  in  duplicate  for  direct  plaques against PC-SRBC and SRBC, and 
for  indirect  plaques  against  T15-SRBC and  SRBC. Most  PFC against  PC are  direct  (14),  and most 
PFC against  T15 are indirect  (13).  Except  when noted,  only direct  PFC to  PC-SRBC and indirect 
PFC to  T15-SRBC and  SRBC were assayed.  When direct  PFC to  TNP were  assayed,  the  procedure 
was the same as previously  reported (14).  For direct  PFC, slides  were incubated  first  in a moist 
chamber and then with complement. For indirect  PFC, slides  were incubated with developing 
serum after  the initial  incubation;  the slides  were drained and washed once in HBSS and then 
incubated with  complement. Each incubation period  was I h. Complement was frozen  guinea  pig 
serum (Grand  Island  Biological  Co.,  Grand Island,  N. Y.)  diluted  1:30  in  HBSS. Developing  serum 
was a goat anti-mouse Ig exhaustively absorbed with T15 and diluted  1:1,000  in HBSS. In some 
preliminary experiments, PFC against  T15-SRBC were  enumerated  using  Cunningham chambers 
and equal parts of  fresh  whole normal mouse and guinea pig serum as complement (13,  15);  in 
repeated experiments, equivalent results  were obtained using  either  this  procedure or  the devel- 
oping serum and agarose slides. 
The magnitude of  a response was calculated  from counts of  two slides  minus the background 
response to  SRBC, which  rarely  exceeded  1,000  PFC of  any  kind  for  the spleen  and 100  PFC of  any 
kind for  a lymph node. The experiments  reported in detail  included more than 100  normal A/He 
mice assayed for  "background" spleen PFC against PC-SRBC, T15-SRBC, and SRBC. The num- 
bers of PFC against PC-SRBC and T15-SRBC were rarely  greater than PFC against SRBC; 
therefore,  the background response of normal mice was not taken into  account in reporting 
responses. 
Results 
The conditions for the experiments to be reported in detail were selected  on 
the  basis  of previous  findings  (4,  5,  13,  14)  and  on  a  series  of preliminary 
experiments  which established  appropriate  doses of antigen,  tissue  sites,  and 
times  for assaying  responses.  In the  present  studies three  PC  antigens  were 
used:  R36A vaccine,  PC-KLH, and the C-polysaccharide  of  R36A vaccine.  Each 
of  these  in  saline  injected  intravenously  induced  similar  spleen  PFC responses  to 
PC-SRBC but little  or no response detectable  in lymph nodes. Repeated injec- 
tions  of  PC-KLH in  adjuvants (using  either  FCA or  B.  pertussis  vaccine  in  FIA 
for  the  first  injection)  in  hind  foot  pads  induced  a  high  PFC response  in  popliteal 
lymph nodes but little  or no detectable  response in other lymph nodes or the 
spleen. 
Whereas  the  response  to  PC  could  be  measured  in  either  the  spleen  or 
popliteal lymph nodes depending on the immunization procedure, this was not 
the case for T15. Mice repeatedly injected intravenously with a range of doses of 
T15 in saline had no detectable spleen PFC or serum antibody response to T15- 
SRBC.  However, T15 mixed with adjuvants and injected in abdominal skin or 
hind foot pads two or more times at weekly intervals induced serum antibody to 
T15-SRBC. Responses were highest when FCA rather than FIA was used for the 
2  Sera pools  from normal A/He mice may have very low titers  against SRBC; titers  of  normal 
serum against PC-SRBC  or T15-SRBC were never higher than titers  against SRBC  alone. 
Immunization  with  PC or  T15 did  not  cause  any  detectable  rise  in  titers  to  SRBC. No  attempt  was 
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first immunization.  (B. pertussis vaccine was not tested.) By using injections in 
hind foot pads, the predominant response was initially limited to the popliteal 
lymph nodes, though a considerable splenic response did occur after four or more 
injections (unpublished observations).  The following experiments demonstrate 
the kind of responses obtained using the immunization  procedures selected for 
subsequent experiments. 
The Response to Immunization with PC or T15.  Mice were injected every 7 
days either intravenously with vaccine or in hind foot pads with PC-KLH or T15 
in adjuvants.  Groups of three mice were sacrificed 2,  4,  and 7 days after each 
immunization.  Peak spleen PFC  responses were always 4 days after the  last 
immunization  with vaccine.  No demonstrable response occurred after a  single 
immunization in hind foot pad with either PC-KLH or T15. The results obtained 
4  days after  one  to  three  immunizations  are  shown  in  Table I.  Though  not 
reported in Table I, immunization with PC antigens did not induce a detectable 
response to T15,  and  immunization  with T15 did not induce a  detectable re- 
sponse to PC. 
Preimmunization with T15 Suppresses the Response to PC.  In preliminary 
experiments  mice were challenged  intravenously with vaccine  1 wk after the 
last of weekly immunizations  in foot pads with T15;  the response to PC  was 
assayed 2, 4, 5, and 10 days later. Mice preimmunized once with T15 invariably 
had normal responses to PC. An occasional mouse (2 of 16 in four experiments) 
immunized  twice  with  T15  had  reduced  responses  to  PC.  In  contrast,  mice 
preimmunized three times with T15 always had reduced responses to PC (exp. 1, 
Table II),  a  finding confirmed  in two additional  experiments  also reported in 
Table II. Mice challenged for as long as 5 wk after the last immunization with 
T15  were markedly  suppressed.  Preimmunization  with  T15  did not suppress 
responses  to  SRBC  or  TNP;  furthermore,  preimmunization  with  a  non-PC- 
binding IgA mouse myeloma protein failed to suppress the response to PC. Thus, 
insofar as was tested, suppression by preimmunization with T15 was specific. 
Preimmunization  with T15 also suppressed the response to PC-KLH injected 
intravenously (unpublished observations) or injected with adjuvants in hind foot 
pads.  For the latter observation,  mice received three weekly injections of T15 
given  in  depots  in  abdominal  skin  using  FCA  for  the  first  immunization. 
Beginning  1 wk after the  last preimmunization,  mice  were injected twice at 
weekly intervals in hind foot pads with PC-KLH in FIA using pertussis vaccine 
for the first immunization.  Popliteal lymph nodes were assayed 4 days after the 
second injection. Four of four preimmunized mice had fewer than 100 PFC to PC- 
SRBC per popliteal lymph node while mice immunized only with PC-KLH had a 
mean of 2,192 (3.34 _+ 0.05) PFC to PC-SRBC per popliteal lymph node. 
Preimmunization  with PC Suppresses  the Response to T15.  In a  series of 
experiments  mice were preimmunized  either once, twice,  or three times with 
PC-KLH in adjuvants or intravenously with vaccine. The mice were challenged 
in hind foot pads with T15 beginning i  wk after the last immunization with PC. 
Popliteal lymph nodes were assayed 4 days after the second injection of T15. 
Mice preimmunized  once or twice with PC had normal  or only slightly lower 
responses to T15; in five experiments mice preimmunized three times with a PC 
antigen had responses to T15 suppressed by three- to fivefold, as is shown for one 
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TABLE  I 
Response to Immunization with PC or T15 
Immunization* 
Response* 
No,  of immunizations 
1  2  3 
R~A  vaccine i,v.  Log~o PFC per spleen to  PC  4.41 ± 0.21  4.22 ± 0.16  3.88 ± 0.12 
Logs serum antibody tAter  to  PC  6  5  6 
Pc-KLH + adjuvants in  foot  pads  Log~o PFC per lymph node to PC  <2.0  3.82 ± 0.09  3.68 ± 0.07 
Log~ serum antibody tAter to PC  0  4  4 
TI5 + adjuvants in foot  pads  Log,o  PFC per  lymph node to  TI5  <2.0  3.44 ± 0.15  3.~5 _--  0,05 
Logz serum antibody tAter to T15  0  4  8 
* Mice were immunized every 7 days. 
* Responses were measured 4 days aRer the last  immunization.  Each mean ± SEM  calculated  on log transformed data is  for a 
group of  three mice. Each antibody tater  is  for  serum pooled from three mice. 
TABLE  H 
Preimmunization with T15 Suppresses the Response to PC 
Immunization*  Responses 
Preimmunization  Challenge im- 
munization  Log~o PFC per spleen to Pc 
Loglo PFC per 
spleen to TNP 
Exp.  1 
T15  Pc  2.45 ~  0.67 t 
None  Pc  4.48 *  0.10  t- <  0.015 
Exp. 2 
T15  Pc  2.12 +_ 0.18 (p <  0.001  I  None  Pc  4.58 + 0.07 
Exp. 3 
T15  Pc  2.76 -+ 0.59 ~p 
None  Pc  4.24 ÷ 0.11 ~  < 0.050 
3.05 -+ 0.01 
3.02 +_ 0.14 
M315  Pc  4.72 _+ 0.10  3.15 -  0.14 
T15  DNP  <2.0  4.80 +- 0.10 
None  DNP  <2.0  4.81 +_ 0.12 
M315  DNP  <2.0  5.03 +- 0.07 
* Mice were preimmunized  in hind foot pads once a week for 3 wk and challenged intravenously  1 
wk after the third preimmunization  in experiments 1 and 3 and after 5 wk in exp. 2. 
$ Responses  were assayed  4  days  after  the challenge  immunization.  Each  mean _+  SEM calculated 
on log  transformed  data is  for  a group  of  four  or  five  mice. Additional controls  in  exps. 1 and 2 
included  groups  preimmunized with  T15 and  untreated  mice injected  intravenously with  0.2  ml 
5% SRBC; preimmunization  with  T15  enhanced  mean responses to  SRBC by  two- and threefold. 
preimmunized mice challenged in foot pads with 20% SRBC substituted for T15, 
or preimmunized mice challenged intravenously once with TNP-Ficoll. Preim- 
munization  with  PC  had  no  effect  or  slightly  enhanced  responses  to  these 
antigens. 
Equivalent suppression of the responses to T15 was obtained when relatively 
large amounts of serum from mice immunized three or more times with PC was 
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TABLE HI 
Preimmunization  with Pc Suppresses the Response to T15 
951 
Immunization*  Responses 
Preimmunization  Challenge im-  Loglo  PFC per lymph node  Loglo  PFC per  lymph 
munization  to  T15  node to  SRBC 
Exp. 1 
<2.0  Pc  T15  2.95 -+ 0.19  p  < 0.005 
None  T15  3.75 + 0.30  <2.0 
Exp. 2 
Pc  T15  2.51 _+ 0.22| p  <2.0  <  0.050  None  T15  3.22 ÷ 0.18 ~  <2.0 
Pc  SRBC  <2.0  3.20 _+ 0.06 |p > 0.200  f  None  SRBC  <2.0  3.20 + 0.15 
* In exp.  1 mice were preimmunized in abdominal skin once a week for 3 wk and challenge 
immunized in hind foot pads beginning 1 wk aRer the third preimmunization. In exp. 2 mice 
were passively immunized with syngeneic antiserum having an anti-PC titer of 7; 0.8 ml was 
given 4 h before the first and 0.6 ml was given 4 h before the second challenge immunization. 
$ Responses were assayed 4 days after the second challenge immunization. Each mean _+ SEM 
calculated on log transformed data is for a group of five mice in exp. 1 and for a group of three 
mice in exp. 2. In other experiments, preirnmunization with PC as done in exp.  1 enhanced 
responses to SRBC or TNP-Ficoll by two- to threefold. 
injected intraperitoneally with a  total of 1.4 ml of serum having a  titer of 7 for 
PC; 0.8 ml was injected 4 h  before the first immunization in hind foot pads; 0.6 
ml was injected 1 wk later, 4 h before the second immunization in hind foot pads. 
Whereas the passively given antiserum suppressed immunization with T15,  it 
had no detectable effect on immunization with SRBC  (exp. 2; Table III). 
The Failure ofT15 Alone or the C-Polysaccharide of R36A Vaccine Alone to 
Prevent Induction of Complementary Responses.  Preimmunization  with  T15 
suppressed  immunization  with  PC,  presumably by inducing  antibody  to  T15; 
however,  it might be argued that T15 was released from the depots of T15  in 
adjuvants  and  suppressed  by  combining  with  the  PC  antigens.  This  seems 
unlikely  for  several  reasons.  First,  sera  from  mice  bled  after  one  or  more 
immunizations  with  T15  in  adjuvants  had  no  detectable  agglutinins  for  PC- 
SRBC;  second,  mice immunized with T15 using only FIA were not suppressed 
(unpublished observations). Furthermore, injections of T15 at the time of immu- 
nization  with  PC  had  relatively little  effect on the  response to  PC.  This was 
demonstrated by injecting mice with either 75/~g or 375/~g ofT15 in saline 1 day 
before intravenous  immunization with vaccine. The smaller amount,  equal to 
the total amount used to immunize three times with T15 in adjuvants,  did not 
suppress while the  larger dose suppressed only slightly,  though the  mice had 
high  agglutinin  titers  for  PC  from the  T15  given  passively  (Table  IV).  The 
failure ofT15 to suppress is consistent with the observation that the Fc portion of 
Ig plays  an  important  role  in  antibody-mediated  suppression  of the  antibody 
response (16,  17). 
The  effect of a  circulating  PC  antigen  on immunization  with  T15  was  also 
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TABLE  IV 
The Failure ofT15 in Saline to Inhibit Immunization with PC 
Immunization*  Responses 
Preimmunization  Challenge im-  Log~o  PFC per spleen  Log2  serum an- 
munization  to PC  tibody to PC 
375 ~g T15  PC  4.07 +_ 0.05  8 
75 ~g T15  PC  4.71 _+ 0.11  5 
None  PC  4.65 +_ 0.10  3 
* Mice were injected intravenously with T15 in saline 1 day before intravenous 
challenge immunization with R36A vaccine. 
¢ Responses were assayed 4 days aider challenge immunization. Each mean _+ SEM 
calculated on log transformed data is for a group of  five mice. Each antibody titer is 
for serum pooled  from  five  mice. 
R36A vaccine induces a good anti-PC response in mice, whereas injection of 400 
~g induces immunologic paralysis to PC (13). Injection of  the larger dose results 
in levels of polysaccharide of about 50 ~g/ml 1 day later and 5 ~/ml of serum 1 
wk later (13). Mice were injected intravenously with 400 ~g of  the C-polysaccha- 
ride either 1 wk or 1 day before beginning immunizations with T15 in adjuvants; 
popliteal lymph nodes were assayed 4 days after the second weekly injection of 
T15. As shown in Table V,  a  "paralyzing dose" of C-polysaccharide had little 
effect on  the  response to T15.  Thus,  the  suppression  of the  response to T15 
produced by repeated immunization with PC was probably due to induction of 
antibody to PC rather than to release of PC antigen which combined with T15. 
Taken together, our findings indicate that antibody passively given or ac- 
tively produced can suppress  induction of a  complementary response.  In the 
following experiments, we tested the effect of  an active response on a previously 
induced complementary response. 
The Failure of Immunization  with T15 to Suppress  either a Secondary or a 
Sustained Response to PC.  Mice were immunized intravenously with vaccine, 
and then beginning 1 wk later were immunized at weekly intervals for 3 wk 
with T15 in adjuvants.  1 wk after the third immunization with T15, the mice 
were again injected intravenously with vaccine. 4 days later spleens and lymph 
nodes were assayed. The results (Table VI) demonstrate that intervening immu- 
nization with T15 suppressed only very slightly the ~'secondary" PFC response to 
PC,  though it did lower the serum antibody titer by greater than  10-fold.  As 
noted in previous experiments, the lymph nodes of mice immunized intrave- 
nously once with PC and then in foots pads with T15 had almost as many PFC to 
T15 as mice immunized with T15 alone; agglutinin titers for T15-SRBC were also 
equivalent. Thus, the initial single immunization with PC had not suppressed 
the final response to immunizations with T15, just as intervening immunization 
with T15 did not suppress the secondary PFC to PC. 
In another experiment mice were immunized intravenously every week with 
PC, and beginning 1 wk after the first immunization they were also immunized 
in  hind  foot pads  with  T15.  Mice  were  killed  after they had  received four 
immunizations with PC and three immunizations with T15. Immunization with 
T15 significantly enhanced rather than  suppressed the  PFC  response to  PC, 
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TABLE  V 
The Failure of a Paralyzing Dose of C-Polysacharide of R36A Vaccine to Inhibit 
Immunization with T15 
Immunization*  Responses 
Preimmunization  Challenge im-  Loglo  PFC per  lymph  LOglo  PFC per spleen 
munization  node to  T15  to PC 
C-polysaccharide-7 days  T15  3.65  ±  0.21 
C-polysaccharide- 1 day  T15  3.49 ±  0.09 
None  T15  3.84 ±  0.13 
m 
C-poplysaccharide -  7 days  PC 
None  PC 
3.15 _+ 0.06 [p 
<0.001 
4.74 +  0.22 
* Mice were injected intravenously with 400/~g of the C-polysaccharide of R36A vaccine before two 
challenge  immunizations in  hind foot  pads  with  T15  in  adjuvants  or  a  single  intravenous 
injection of R36A vaccine. 
S Responses were assayed 4 days after the second challenge immunization with T15 or 4 days after 
the single challenge immunization with vaccine.  Each mean _  SEM calculated on log trans- 
formed data is for a  group of four mice. 
VII). Neither the numbers of lymph node PFC nor the levels of serum antibody 
to T15 were affected appreciably by immunization with PC. The experiment was 
repeated except that mice were killed after five immunizations with PC  and 
after four immunizations with T15. Again, immunization  with T15 enhanced the 
number of PFC to PC but reduced serum antibody to PC significantly, and as in 
the experiment reported in Table VI immunization with PC did not measurably 
affect the response to T15. 
The  Biological  Activity  of  Serum  from  Mice  Immunized  with  T15  or 
PC.  Sera were pooled from mice bled 4 days after three immunizations with 
T15; one pool was from appropriate mice in experiments done early in the course 
of this work, and the other pool was from appropriate mice in experiments done 
near the conclusion of  the work reported here. The first pool had a titer of 11 and 
the second pool a titer of 9 for T15-SRBC. Neither pool had detectable aggluti- 
nins for PC-SRBC.  Both pools,  final dilution of 1:200 in  cultures of BALB/c 
spleen cells, completely suppressed the response to immunization with vaccine 
while control cultures without added sera had >1,000 PFC to PC per culture. 
These sera did not suppress the response in vitro to immunization with SRBC or 
TNP. 12 neonatal BALB/c mice from three litters were given 0.1 ml of  one or the 
other pool; the mice were completely unresponsive to PC when immunized with 
vaccine 6-18 wk later; all of 9 littermates which did not receive sera and were 
similarly immunized with vaccine had >25,000 PFC per spleen. Four adult A/ 
He mice given 0.3 ml of the first pool 1 day before immunization with vaccine 
had PFC responses to PC of <500 per spleen while three controls immunized 
similarly with vaccine had  >10,000  PFC per spleen; the second pool was not 
tested in adult mice.  Thus,  the A/He mice as  immunized with T15  in these 
experiments produced antisera which had activity similar to sera obtained from 
mice immunized more intensely as reported in previous experiments (6, 7). 
In addition, serum pooled from five mice immunized three times with T15 in 
adjuvants and a  pool from five mice immunized three times with R36A were 
tested for inhibition of plaque formation using cells producing complementary 954  SUPPRESSION  BY  AUTOGENOUS  COMPLEMENTARY  IDIOTYPES 
TABLE  VI 
A Secondary PFC Response to PC Was Not Suppressed by Immunization with T15 
Immunization*  ResponseS, § 
Preimmuni-  Intervening  Challenge  Log2 serum an- 
immuniza-  immuniza-  Log~0  PFC per spleen to Pc  tibedy titer to  zation  tion  tion  Pc 
PC  T15  Pc  4.39  ±  0.06 ~  3 
PC  None  Pc  4.76  +  0.14~  t  p  <  0.050  7 
None  T15  Pc  <2.0  |  1  P  <  o.ooi  None  None  Pc  4.34 +- 0.09 {  2 
PC  T15  None  3.22 _+ 0.15 ~  2 
PC  None  None  3.29 + 0.05 L  f p  > 0.400  1 
* Mice preimmunized once with R36A vaccine given intravenously were injected in foot pads with 
T15 in adjuvants beginning 1 wk later.  1 wk after the third injection  of T15, the mice were 
challenged  intravenously with vaccine. Controls were injected as indicated. 
$ Responses were measured 4 days al~er the challenge immunization. Each mean _  SEM calcu- 
lated on log transformed data is for a group of four mice. Each antibody titer is for serum pooled 
from four mice. 
§ Popliteal lymph nodes were pooled from mice in each group immumzed with T15. The pools 
contained equivalent numbers (log~o =  3.I0-3.12)  of PFC/node  to T15-SRBC. Also,  all three 
pooled sera from these groups had a log~ antibody titer to T15-SRBC of 11. 
antibody.  Spleen  cells  obtained  frora  mice  injected  once  intravenously  with 
R36A vaccine were mixed with PC-SRBC  in agarose; 50  ~l of a  dilution of the 
anti-T15 serum  was added,  and  the  mixture was spread on a  slide;  the  slides 
were processed as usual  for demonstrating  PFC  to PC.  Similarly,  slides were 
prepared using popliteal lymph node cells obtained from mice immunized twice 
with T15 in adjuvants, T15-SRBC, and dilutions of the anti-PC serum. Anti-PC 
plaque formation was completely inhibited by a  dilution of the anti-T15 serum 
which  would  give  an  estimated  agglutinin  titer  of three  to  four  in  the  cell- 
agarose  mixture.  Similarly,  the  anti-PC  serum  completely  inhibited  plaque 
formation by cells releasing anti-T15 with a  dilution of the serum which would 
give an estimated titer of four in the cell-agarose mixture.  Neither antiserum 
inhibited plaque formation by cells immunized against SRBC. 
Discussion 
It  seems  reasonable  to  assume  that  antibody,  whether  given  passively  or 
induced actively, suppressed induction of a complementary response by interact- 
ing  with  complementary  receptors  on  immunocompetent  cells.  Presumably, 
such  suppression  is  a  function  of the  class,  quantity,  and  specificity  of the 
"regulating" antibody; and possibly the resulting effect is modified by a  shift in 
the  "idiotype" of the  regulated  response  (18).  To date,  we have not  examined 
these variables in a  systematic way. We know that immunization with T15 in 
adjuvants  induces  in pepliteal lymph nodes cells which  release IgG1 and IgG2 
against T15 (unpublished observations). Also, we detected indirect PFC to PC in 
mice immunized multiple times with PC but not in mice immunized once with 
PC. But we have not compared classes of purified antibodies for their capacity to ROWLEY,  KOHLER,  SCHREIBER,  KAYE,  AND  LORBACH  955 
TABLE  VII 
A Sustained Response to PC Was Not Suppressed by Superimposed Immunization with 
T15 
Immunization*  Response~ 
To PC  To T15 
PC  T15  Log2 serum  Log~o  PFC for  Log2 serum 
Loglo PFC per spleen  antibody  lymph nodes  antibody 
titer  titer 
4  ×  3  ×  4.38 -+ 0.29[p<0.10  2  4.15 _+ 0.07  10 
4  ×  None  3.87 +  0.07[  6  -  0 
None  3  ×  <2.0  0  4.43 _+ 0.21  9 
* Mice immunized with both antigens were injected intravenously every 7 days with R36A vaccine 
and beginning with the second immunization they were also injected in hind foot pads with T15 
in adjuvants. Controls were injected with one or the other antigen only. 
* Responses were measured 4 days after the last immunization. Each mean _  SEM calculated on 
log transformed data is for a group of five mice. Each antibody titer is for serum pooled from five 
mice. 
cause  suppression  or  possibly to  stimulate  responses  when  given  passively. 
Eichmann,  using heterologous anti-idiotypic antibody, found that IgG1  stimu- 
lated  while  IgG~  suppressed  responses  (19).  If Eichmann's  findings  can  be 
extrapolated in a general way to the function of autogenous antibody, then the 
resultant effect of suppression or stimulation will depend on the ratio of classes 
of antibody produced. 
Presumably, only antibodies direct against combining site structures of com- 
plementary antibody or receptors are involved in regulation of that particular 
response, but a priori, there is no reason why antibodies produced by different 
clones could not be directed against different portions of the receptor. If this is 
the case, then antibodies of different specificities may vary in effectiveness in 
blocking or altering receptor function.  However, this variability may be mini- 
mal  in  our  model  because  the  response  to  PC  is  predominantly  of a  single 
idiotype (14, 20-24), though antiserum to T15 may contain antibody to determi- 
nants  outside  the  combining  region  and  a  determinant  limited  to the  heavy 
chain (20, 21, 24). We find that antiserum to PC in low titer will inhibit plaque 
formation by cells from mice immunized with T15 whether or not the mice have 
a  simultaneous  response to  PC;  similarly,  antiserum  to T15 in  low titer  will 
inhibit plaque formation by cells from mice immunized with PC whether or not 
the mice have a simultaneous response to T15 (unpublished observations). Thus, 
to the limited extent we have examined the problem,  we have not detected a 
change in combining site determinants of antibodies from mice having simulta- 
neous complementary responses. 
The present experiments provide no evidence that complementary antibodies 
cause  '~feedback"  suppression  once  immunization  has  occurred.  Apparently, 
once a  clone has been stimulated and expanded by immunization,  complemen- 
tary antibody does not reduce the number of cells in the clone which can produce 
antibody.  Thus,  immunization  with  T15  did  not  suppress  a  secondary  PFC 
response to PC; however, simultaneous immunization did lower serum antibody 956  SUPPRESSION  BY  AUTOGENOUS  COMPLEMENTARY  IDIOTYPES 
titers  to  PC  very substantially  (Tables  VI  and  VII).  Lower levels  of serum 
antibody may have occurred because of formation of complexes.  When serum 
containing antibody to PC is mixed with serum containing antibody to T15, the 
specific antibody activity of each serum is partially quenched, though mixtures 
prepared  in different ratios may still  have activity to one,  the other,  or both 
antigens  (25).  Thus,  serum  antibody  titers  from  mice  having  simultaneous 
complementary responses may reflect the fact that two responses have occurred, 
but  such  titers  may  indicate  inaccurately  the  magnitude  of each  of the  re- 
sponses. Though it seems most likely that the lower level of serum antibody to 
PC resulted from formation of complexes with antibody to T15, it is conceivable 
that high levels of circulating anti-T15 may suppress in vivo the syntheis and/or 
release of anti-PC antibody from cells. If this were the case, then removal of the 
cells from the milieu of antibody to T15 and washing them may reverse suppres- 
sion so that the cells were identified and enumerated  as PFC. At present we 
cannot confirm or rule out this possibility. 
The response  of A/He mice to immunization  with  PC is about 5- to 10-fold 
lower than for BALB/c mice, but A/He mice immunized with T15 have about 5- 
to 10-fold higher responses than BALB/c mice (unpublished observations). Pre- 
sumably these differences are a function of the relative sizes of the clones which 
in turn  are  genetically determined.  However, a  response  may be suppressed 
when a  complementary response has been induced first.  Possibly the relative 
unresponsiveness  of BALB/c mice to immunization  with T15  is partly due to 
their high background anti-PC response resulting from exposure to environmen- 
tal PC-containing antigens  (26).  Certainly we find much higher levels of back- 
ground serum antibody and spleen PFC to PC in BALB/c than in A/He mice, but 
we have not attempted to correlate the magnitude of induced anti-T15 responses 
with background levels of antibody to PC in individual mice. 
Specific suppression can be mediated by cells, and it is possible that suppres- 
sion observed in actively immunized mice was caused by cells in addition to or 
rather than by antibody. But regardless of the mechanism,  the present experi- 
ments  and  those  reported  earlier  (27)  demonstrate  quite  dramatically  that 
specific suppression can be induced by immunization  with antigens which can 
not be considered cross-reacting in any conventional sense. In both studies the 
myeloma proteins used as antigens were injected multiple times with adjuvants. 
Also, polymerization of BALB/c myeloma protein enhanced immunogenicity of 
the  protein  for  BALB/c  mice  (28);  similarly,  autoantibody  was  purified  and 
polymerized to induce autoanti-idiotypic antiserum (29). The relevance of these 
kinds of studies to autoregulation of responses may be questioned legitimately 
because of the  vigorous manipulations  necessary to  make  autoantibody anti- 
genic (30). On the other hand, anti-idiotypic antibody has been used to stimulate 
an anti-PC response in vitro (31),  and antigen-antibody complexes in antibody 
excess may induce complementary or autoanti-idiotypic antibodies in vivo (9, 10, 
32).  Conceivably,  antibody  of any  specificity,  complexed  in  excess  with  its 
antigen,  may function  as  an  antigen  and  induce  a  complementary  response. 
Possibly most or all antibodies might be thought of as complementary to some 
other antibody in the antibody repertoire of an individual and be considered part 
of an extensive network (33). ROWLEY, KOHLER, SCHREIBER, KAYE, AND  LORBACH  957 
Summary 
Complementary idiotypes or antibodies are considered to have combining site 
structures which are at least partly directed against each other. Complementary 
antibodies were induced in A/He mice by immunization with phosphorylcholine 
(PC)-containing antigens and by immunization with the PC-binding IgA mye- 
loma protein TEPC-15  (T15). Both responses were monitored by enumerating 
plaque-forming cells  (PFC)  and  assaying serum  antibody levels against the 
corresponding  antigens.  Mice  immunized at  least  three  times  with  T15  in 
adjuvants had markedly suppressed responses to subsequent immunization with 
PC;  similarly',  mice  preimmunized  multiple times  with  PC  had  suppressed 
responses to immunizations with T15. In contrast, mice immunized with T15 in 
the interval between "primary" and "secondary" immunizations with PC  had 
undiminished PFC responses to both antigens but significantly decreased anti- 
body titers to PC. Simultaneous responses were also induced by immunizations 
with T15  superimposed on weekly immunizations with PC; with this regime, 
immunization with T15 actually enhanced the PFC response to PC, but serum 
antibody to PC was significantly lower than for mice immunized with PC only. 
Levels of serum antibody to PC were probably lower, either because anti-PC 
antibody was complexed with the complementary antibody directed against T15, 
or because the antibody directed against T15 prevented synthesis and/or release 
of anti-PC  antibody by cells  in vivo.  Thus,  an established prior  autogenous 
immune response can dramatically suppress a subsequent primary complemen- 
tary response,  but the effects of complementary responses on each other are 
more complex with different sequences of immunization. Also,  the effects of 
variables such as the amounts and ratios of the classes of antibodies on regula- 
tion of complementary responses remain to be defined. 
Received for publication 22 March 1976. 
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